Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 8;162(9):2376–2385. doi: 10.1097/j.pain.0000000000002223

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 4. — Time course of plasma AEA and PEA levels after NTG administration in MIG+ and MIG− subjects. T30, T60, and T120: evaluations at 30, 60, and 120 minutes after nitroglycerin (NTG) administration (0.9 mg sublingual). MIG+: subjects with episodic migraine and a positive migraine-induction test (n = 16). MIG−: subjects with episodic migraine and a negative migraine-induction test (n = 8); Statistical analysis: 2-factor ANOVA for repeated measures (factor “HEADACHE” with 2 levels: MIG+ vs MIG−; factor “TIME” with 4 levels: Baseline, T30, T60, T120): Plasma AEA levels (A): TIME: P = 0.169; HEADACHE: P = 0.909; TIME × HEADACHE: P = 0.872. Plasma PEA levels (B): TIME: P = 0.021; HEADACHE: P = 0.341; TIME × HEADACHE: P = 0.513. AEA, anandamide; ANOVA, analysis of variance; PEA, palmitoylethanolamide.